Benjamin Pradere

Live podcast #EAU26 @MichvdHeijden - the original source of ‘EVP 1st, ask questions later’ describes a new world of short periods on systemic therapy for MIBC followed by decision making uncertainty for the cCRs . @UroDocAsh & myself advocates for sticking to the protocol (EVPX9 and surgery) , but @brian_rini @shilpaonc think other patterns will emerge. @urotoday

It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs. This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT. And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT. Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression. If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics. This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26 @UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi